Risks and Benefits of Interferon-α in the Treatment of Hepatitis
- 1 November 1995
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 13 (5) , 304-316
- https://doi.org/10.2165/00002018-199513050-00004
Abstract
No abstract availableKeywords
This publication has 96 references indexed in Scilit:
- The Use of Interferon-α in Virus InfectionsDrugs, 1991
- Role of hepatitis delta virus infection in hepatocellular carcinomaDigestive Diseases and Sciences, 1991
- Hepatitis B: global importance and need for controlVaccine, 1990
- Treatment of chronic hepatitis B with interferon alfa-2bJournal of Hepatology, 1990
- Recombinant Interferon Alfa Therapy for Chronic Hepatitis CNew England Journal of Medicine, 1989
- Treatment of Chronic Hepatitis C with Recombinant Interferon AlfaNew England Journal of Medicine, 1989
- Treatment of chronic delta infection with recombinant human interferon alpha 2c at high dosesJournal of Hepatology, 1989
- Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective studyLiver International, 1989
- Chronic non‐A, non‐B hepatitis developed after transfusions, illicit self‐injections or sporadically. Outcome during long‐term follow‐up – a comparisonLiver International, 1989
- Treatment of Chronic Non-A, Non-B Hepatitis with Recombinant Human Alpha InterferonNew England Journal of Medicine, 1986